Search

Travere Therapeutics Inc

Deschisă

51.82 -0.59

Rezumat

Modificarea prețului

24h

Curent

Minim

51.47

Maxim

53.22

Indicatori cheie

By Trading Economics

Venit

1.8M

-35M

Vânzări

42M

170M

EPS

-0.37

Marjă de profit

-20.519

Angajați

497

EBITDA

-24M

-33M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+45.64% upside

Dividende

By Acuity

Următoarele câștiguri

29 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

250M

5.4B

Deschiderea anterioară

52.41

Închiderea anterioară

51.82

Travere Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 oct. 2026, 23:51 UTC

China's Inflation Rate YoY for September 2026 set to release on October 14, with expectations of a slight increase to 0.1%, amid cautious market sentiment influenced by global economic factors and U.S. Treasury yields.

11 oct. 2026, 23:51 UTC

China's PPI data release on October 14, 2026, expected to show a year-on-year increase of 4.5%, amid cautious optimism and potential implications for global inflation and monetary policy.

11 oct. 2026, 23:51 UTC

China's inflation rate expected to rise by 0.3% MoM amid cautious market sentiment and global economic pressures ahead of key CPI reports.

11 oct. 2026, 23:41 UTC

U.S. Import Prices Report on October 16 Forecasts 0.7% Increase Amid Cautious Market Sentiment and Geopolitical Tensions

11 oct. 2026, 23:41 UTC

U.S. Export Prices Expected to Rise 0.01% in September Amid Mixed Economic Sentiment and Cautious Market Optimism

11 oct. 2026, 23:31 UTC

Canada's Housing Starts Data Release on October 16 Forecasts Decline to 237.5K Units Amid Cautious Market Sentiment

11 oct. 2026, 23:21 UTC

Core Producer Price Index (PPI) for September 2026 set to release on October 15, with a forecasted increase of 0.3%, amid mixed economic sentiment and rising Treasury yields impacting investor optimism.

11 oct. 2026, 23:21 UTC

Market Braces for September PPI Release Amid Rising Treasury Yields and Fed Rate Hike Speculation

11 oct. 2026, 23:21 UTC

Market Awaits Philadelphia Fed Manufacturing Index Release Amid Mixed Economic Sentiment and Caution Over Inflationary Pressures.

11 oct. 2026, 23:21 UTC

Investors Brace for NY Empire State Manufacturing Index Release Amid High Treasury Yields and Inflation Concerns on October 15, 2026.

11 oct. 2026, 23:11 UTC

Australia's Full-Time Employment Change Data Set for Release on October 15, Anticipated to Reflect Economic Resilience Amid Global Challenges.

11 oct. 2026, 23:11 UTC

Australia's September 2026 unemployment rate forecasted to rise to 4.6%, raising market concerns ahead of the October release amid global economic volatility.

11 oct. 2026, 23:11 UTC

Australia's Employment Change Report on October 15 Expected to Show Job Growth Amid Positive Labor Market Sentiment, but Analysts Warn of Potential Volatility.

11 oct. 2026, 23:01 UTC

Investors Brace for Volatility Ahead of October 14 CPI Release Amid Rising Inflation Concerns and Fed Rate Hike Speculations.

11 oct. 2026, 23:01 UTC

Core Inflation Rate for September 2026 set to rise by 0.2%, influencing market sentiment and Federal Reserve rate hike expectations ahead of key CPI reports.

11 oct. 2026, 23:01 UTC

U.S. CPI Expected to Rise to 336.67 Amid Inflation Concerns and Market Volatility Ahead of October Release

11 oct. 2026, 23:01 UTC

Core Inflation Rate YoY for September 2026 set to rise slightly to 2.5%, as markets brace for potential Federal Reserve interest rate hikes amid geopolitical tensions and high Treasury yields.

11 oct. 2026, 23:01 UTC

Investors Brace for U.S. CPI Release on October 14, Anticipating Inflation Rise to 3.7% and Potential Fed Policy Shifts

11 oct. 2026, 23:01 UTC

U.S. Inflation Rate Expected to Rise 0.6% in September Amidst Market Caution and High Treasury Yields Ahead of Federal Reserve Decisions

11 oct. 2026, 23:01 UTC

Macro News

Gold prices are declining amid escalating geopolitical tensions and rising U.S. Treasury yields, remaining below its 20-day moving average.

11 oct. 2026, 23:01 UTC

The EUR/NOK is advancing in early trading, influenced by geopolitical tensions and rising yields.

11 oct. 2026, 23:01 UTC

The EUR/SEK is trading higher in early trading, rebounding after a slight dip amid rising yields and geopolitical tensions affecting market sentiment.

11 oct. 2026, 22:51 UTC

Brazil's Retail Sales MoM data for August 2026, expected to rise by 0.8%, set for release on October 15 amid cautious economic sentiment influenced by global trends.

11 oct. 2026, 22:31 UTC

Japan's Machinery Orders MoM data set for October 14, with a modest growth forecast of 0.03% amid cautious market sentiment following recent volatility.

11 oct. 2026, 22:31 UTC

RBA Meeting Minutes on October 13 Expected to Address Inflation Concerns and Future Monetary Policy Adjustments.

11 oct. 2026, 22:31 UTC

Australia's NAB Business Confidence Report Set for Release Amidst Cautious Market Sentiment and Ongoing Economic Challenges

11 oct. 2026, 22:21 UTC

Singapore's Q3 2026 GDP Growth Rate Expected at 0.9%, Amid Cautious Optimism and Input Cost Concerns

11 oct. 2026, 22:21 UTC

Mortgage Rates Hit 7.49% Amid Rising Treasury Yields and Inflation Concerns, Sparking Caution in Housing Market Ahead of Upcoming Data Release

11 oct. 2026, 22:11 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights Amid Political Turmoil on October 13, 2026.

11 oct. 2026, 22:01 UTC

South Korea's September 2026 unemployment rate release on October 15 expected to reveal job market stability amid global inflation concerns.

Comparație

Modificare preț

Travere Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

45.64% sus

Prognoză pe 12 luni

Medie 75.917 USD  45.64%

Maxim 90 USD

Minim 62 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTravere Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

11

Cumpărare

1

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.